| Project outline

RENUM – Renal Function Assessment by Nuclear Magnetic Resonance based Metabolomics

Objective:
Development and validation of an NMR based metabolic constellation determining glomerular filtration rate for a more accurate picture of the underlying kidney function.

 

“A diagnostic test as precise as mGFR, as simple as eGFR, and fit for clinical routine“.

Dr. Eric Schiffer

Head of Clinical Development, numares AG

 

 

 

The glomerular filtration rate (GFR) is the most important parameter in assessing kidney function. The gold standard to determine GFR is inulin clearance [1, 2], but other substances have been explored for measuring GFR (mGFR) as well [3]. Although very precise, mGFR methods are expensive, time-consuming and therefore impractical in routine. Therefore, GFR is mostly estimated by a simple serum creatinine analysis (eGFR) [4]. However, serum creatinine levels strongly depend on patient’s individual features, i.e. muscle mass, age or physical activity level. Thus, this approach is associated with a distinct imprecision. There exist more than 50 eGFR equations illustrating the degree of uncertainty associated with the approach [5]. Based on these facts, there is a clinical need for a test system that combines precision of mGFR approaches with the easy accessibility of eGFR.

Study design:
RENUM is a retrospective multi-center observational study

Material:
Biobanked serum samples of patients with broad spectrum of primary renal diseases and degrees of renal impairment

Reference standard:
mGFR

Approach:
The scientific literature indicates that there is a connection between increasing/ decreasing concentrations of endogenous blood metabolites and the GFR. To establish a combination of endogenous metabolites with creatinine to a metabolic constellation reflecting GFR, numares uses its precise, fast and flexible analytical AXINON® System, which allows simultaneous detection of metabolites in a highly reproducible single analytical step.

Phase 1:
The association of endogenous serum metabolites with GFR will be tested. Quantitative NMR signals of both, literature reported candidates and proprietary metabolic markers, will be correlated with mGFR reference data. Candidates significantly associated with GFR will be used to model renal clearance based mGFR. 

Phase 2:
The diagnostic performance (trueness and precision) of the obtained model(s) will be tested in a further, independent sample set (not used for discovery or modelling).

Success:
Our efforts will result in a novel, simple blood test that will be available for clinical routine in early 2019: AXINON® Clearance Check*.

References: 
1. Smith, H.W., The kidney: Structure and function in health and disease. Oxford University Press Inc, New York, 1951.
2. National Kidney, F., K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis, 2002. 39(2 Suppl 1): p. S1-266.
3. Stevens, L.A. and A.S. Levey, Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol, 2009. 20(11): p. 2305-13.
4. Kemperman, F.A., R.T. Krediet, and L. Arisz, Formula-derived prediction of the glomerular filtration rate from plasma creatinine concentration. Nephron, 2002. 91(4): p. 547-58.
5. Johnson, D. and I. Caring for Australians with Renal, The CARI guidelines. Evaluation of renal function. Nephrology (Carlton), 2005. 10 Suppl 4: p. S133-76.

*numares’ products are not yet available for sale within the United States; they have not yet been approved or cleared by the U.S. Food and Drug Administration.

 

| Events

ERA EDTA 2019

13th - 16th June, 2019
Hungexpo, Budapest, Hungary

 

 

Our Success. |Innovative Diagnostic Products.

Project: PARASOL – Detection of Renal Allograft Rejection by NMR-based Urine Metabolomics

Objective:
Quantitative evaluation of the diagnostic accuracy (AUC value, sensitivity, and specificity) of AXINON® renalTX-SCORE-U100® for the detection of acute renal allograft rejections

“A non-invasive diagnostic test for close-monitoring of kidney transplant patients and minimizing the number of potential graft-harming biopsies for earliest therapy intervention to preserve the kidney“,
Dr. Eric Schiffer, Head of Clinical Development, numares AG

Kidney transplantation is the treatment method of choice for patients with terminal kidney failure [1]. Transplant patients require frequent follow-up examinations to detect potential complications at an early stage. Therefore, biopsies are performed during aftercare. They are generally considered to be safe, but it remains an invasive procedure with a risk...

Learn more

 

Project: BLADE – Bladder Cancer Detection using Metabolomic Evaluation of Urine and Blood

Objective:
Development and Evaluation of a metabolic constellation for the diagnosis of bladder cancer in patients with persistent microhaematuria.

“A minimal invasive diagnostic test for a reliable detection of bladder cancer.“
Dr. Eric Schiffer, Head of Clinical Development, numares AG

Urinary bladder cancer (BCa) is a malignant tumour that usually develops in the mucous membrane (urothelial carcinoma) of the bladder. The symptoms are relatively unspecific. One of the earliest cardinal symptoms of BCa is microscopically detectable haematuria, so-called microhaematuria, [1]. However, microhaematuria commonly has benign causes, such as infection, benign prostate enlargement or...

Learn more

 

Project: HERMES – Hepatocellular Carcinoma Recognition by Metabolomics Analysis of Serum

Objective: 
Development and validation of a metabolic constellation in serum for early detection of hepatocellular cancer.

“A diagnostic screening test for early detection of hepatocellular cancer to supplement abdominal sonography in HCC surveillance.“
Dr. Eric Schiffer, Head of Clinical Development, numares AG

Hepatocellular carcinoma (HCC) is an aggressive tumor of the liver with annual incidence of 1-6% in at risk patients with liver cirrhosis [1, 2]). Most patients have symptoms only in advanced stage HCC, impeding early detection of the tumor. The 5-year survival rate is <10% if HCC is diagnosed after symptoms...

Learn more

 

Project: MUSE – Multiple Sclerosis Biomarker Evaluation

Objective:
Development and Validation of an NMR-based metabolic constellation that early indicates the transition of relapsing-remitting (RRMS) to secondary progressive multiple sclerosis (SPMS). 

“A serum-based test for early diagnosis of the RRMS-to-SPMS transition to allow timely therapy adjustment”
Dr. Eric Schiffer, Head of Clinical Development, numares AG

Multiple sclerosis (MS) is considered to be an immune-mediated disease in which the body’s own defence cells attack the central nervous system. MS involves inflammatory and neurodegenerative processes that damage the insulating myelin sheaths of nerve fibers and the nerve cells themselves.  While about 10-15% of patients begin the disease with primary progressive MS (PPMS) showing continuously worsening of symptoms from disease onset, the majority of patients are initially diagnosed...

Learn more